SMS Lifesciences Share Price

SMS Lifesciences Share Price

NSE: HALEOSLABS
|
Pharmaceuticals
|
S Cap
ā‚¹ 1,451.30
-ā‚¹30.80 (-2.08%)
1D
Last updated 04 Sep, 2026, 15:29 IST

SMS Lifesciences Share Price Today

As of 5 Sep 2026, SMS Lifesciences share price is ā‚¹1,451.30. The stock opened at ā‚¹1,509.40, compared to its previous close of ā‚¹1,482.10. During today's trading session, SMS Lifesciences share price moved in the range of ā‚¹1,441.00 to ā‚¹1,509.40, with an average price of ā‚¹1,475.20 for the day. Looking at its last 52-week, the stock has touched a low of ā‚¹1,091.10 and a high of ā‚¹1,774.00. On the performance front, SMS Lifesciences share price has increased by 13.28% over the last six months and is up 29.89% on a year-on-year basis.

ā‚¹1,441.00
2.08% down today
ā‚¹1,509.40
1D LOW
1D HIGH

SMS Lifesciences Returns Calculator

Circuit
L
H
ā‚¹1,161.10
ā‚¹1,741.50
52-week
L
H
ā‚¹1,091.10
ā‚¹1,774.00

About SMS Lifesciences

SMS Lifesciences Share Price
ISIN
INE320X01016
Sector Market Cap
ā‚¹ 443.76 Cr

Haleos Labs Limited, formerly, SMS Lifesciences India Limited, is an India-based company that is engaged in the business of manufacturing of active pharma ingredients (API) and their intermediates. The Company's API products include Ranitidine Hydrochloride (Form-2) USP / Ph. Eur / IP, Famotidine USP / Ph. Eur / IP, Sildenafil Citrate USP / Ph. Eur / IP, Allopurinol USP / EP / IP, Ropivacaine Hydrochloride USP / EP / IP, Dapsone USP/ EP /BP, Sibutramine Hydrochloride USP, Itraconazole USP / Ph. Eur, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP / IP, Brinzolamide, Tiagabine, Fosaprepitant and Albendazole, among others. Its intermediate offerings include Ranitidine HCl Intermediates, Rizatriptan Intermediates and Imidapril Intermediates. The Company's manufacturing facilities are located at Kazipally and Jeedimetla, and its research and development center is at Sanath Nagar in Hyderabad. The Company's wholly owned subsidiary is Mahi Drugs Private Limited.

SMS Lifesciences Financial Highlights

  • Revenue: SMS Lifesciences reported revenue of ā‚¹336.22 crore in FY26 vs ā‚¹349.58 crore in FY25. It showed a decrease of 3.82% on a yearly basis.
  • Operating Profit: SMS Lifesciences reported an operating profit of ā‚¹25.20 crore in FY26 vs ā‚¹26.19 crore in FY25. It showed a decrease of 3.78% on a year-on-year basis.
  • Net Profit: SMS Lifesciences reported a net profit of ā‚¹17.80 crore in FY26 vs ā‚¹18.73 crore in FY25. It showed a decrease of 4.97% on a yearly basis.

SMS Lifesciences Quarterly Result Highlights

  • SMS Lifesciences reported revenue of ā‚¹73.40 crore in Jun 2026, compared with ā‚¹77.15 crore in Mar 2026, representing a decrease of 4.86% on a quarter-on-quarter (QoQ) basis.
  • SMS Lifesciences reported an operating profit of ā‚¹3.44 crore in Jun 2026, compared with ā‚¹0.91 crore in Mar 2026, representing an increase of 278.02% on a quarter-on-quarter (QoQ) basis.
  • SMS Lifesciences reported a profit of ā‚¹1.84 crore in Jun 2026, compared with ā‚¹0.34 crore in Mar 2026, reflecting an increase of 441.18% on a QoQ basis.
  • The earnings per share (EPS) of SMS Lifesciences stood at ā‚¹66.51 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
72.11%
FII
0.00%
Other DII
0.31%
Retail and other
27.58%
Mutual funds
0.00%
Foreign Institutional Investor (FII)
FII shareholding by period
Sep 20250.00%
Dec 20250.00%
Mar 20260.00%
Jun 20260.00%
Mkt Cap Cr
443.76
P/E
29.08
P/B
2.08
ROE
8.11%
D/E
0.44
ROCE
9.76%
Div. Yield
0.10%
EPS(TTM)
58.80
Turnover
0.72
EV/EBITDA
12.65
Net Margin
0.00%
Op. Margin
0.00%
ROA
3.36%
Quick Ratio
0.00
Curr. Ratio
2.45
Based on fundamentals, this stock's
Step 1 of 5
Performance
Very Poor
Haleos Labs Limited has not beaten FD return of 7%
Step 1 of 5
Valuation
Overvalued
Haleos Labs Limited appears overvalued compared to its peers
Step 3 of 5
Earnings
Neutral
Haleos Labs Limited earnings growth is positive
Peer Comparison
Peer comparison ā€” key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,55,634.0037.605.4513.74%0.6117.33%93.240.84%0.4810.90
Divis Laboratories2,41,576.0082.5914.4115.32%0.0019.56%629.490.33%0.5598.19
Torrent Pharmaceuticals1,84,478.0085.5721.9425.49%1.6913.85%222.760.70%0.4958.70
Zydus Lifesciences1,11,820.0024.354.1218.59%0.3117.35%237.300.09%0.3335.38
Cipla1,11,888.0033.343.2511.27%0.0014.95%423.360.94%0.4543.52
Laurus Labs99,417.5091.1818.7616.77%0.4016.14%97.200.11%0.6713.72
Lupin97,626.3017.394.3023.76%0.0424.88%659.000.85%0.57129.18
Mankind Pharma96,179.6046.525.9011.74%0.3413.13%396.980.04%0.4449.37
Dr. Reddy's Laboratories96,322.1030.262.5311.07%0.1812.54%377.950.69%0.4138.68
Aurobindo Pharma95,127.2025.642.519.25%0.1911.76%394.820.24%0.3841.58

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

SMS Lifesciences Financials

Full statement

Income Statement Ā· Consolidated

Income Statement Ā· Consolidated ā€” all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenueā‚¹344.72ā‚¹305.96ā‚¹315.56ā‚¹350.07
Other Incomeā‚¹4.86ā‚¹3.83ā‚¹3.07ā‚¹1.74
Total Revenueā‚¹349.58ā‚¹309.79ā‚¹318.63ā‚¹351.81
Total Expensesā‚¹323.39ā‚¹299.94ā‚¹304.39ā‚¹331.77
Profit Before Taxā‚¹26.19ā‚¹9.85ā‚¹16.59ā‚¹32.73
Taxā‚¹7.46ā‚¹3.52ā‚¹5.22ā‚¹7.43
Profit After Taxā‚¹18.73ā‚¹6.33ā‚¹11.38ā‚¹25.30
EPS - Basicā‚¹66.51ā‚¹30.08ā‚¹37.92ā‚¹83.76
EPS - Dilutedā‚¹66.51ā‚¹30.08ā‚¹37.92ā‚¹83.76

Cash Flow Ā· Consolidated

Cash Flow Ā· Consolidated ā€” all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before taxā‚¹26.19ā‚¹9.85ā‚¹14.24ā‚¹20.04
Income before WC changesā‚¹50.91ā‚¹31.33ā‚¹30.11ā‚¹34.09
Change in Assets-ā‚¹49.93-ā‚¹40.32-ā‚¹31.16-ā‚¹52.44
Change in Liabilitiesā‚¹41.57ā‚¹36.30ā‚¹19.01ā‚¹14.82
Change in WC-ā‚¹8.36-ā‚¹4.03-ā‚¹12.15-ā‚¹37.62
Cash flow from Operationsā‚¹34.06ā‚¹24.31ā‚¹14.70-ā‚¹11.24
Cash flow from Investing-ā‚¹15.00-ā‚¹18.45-ā‚¹31.29-ā‚¹7.14
Cash flow from Financing-ā‚¹19.12-ā‚¹6.56ā‚¹16.89ā‚¹10.83
Total Cash Flow-ā‚¹0.07-ā‚¹0.71ā‚¹0.29-ā‚¹7.55
Cash (Start of the year)ā‚¹0.57ā‚¹1.28ā‚¹0.99ā‚¹8.54
Cash (End of the year)ā‚¹0.50ā‚¹0.57ā‚¹1.28ā‚¹0.99

Balance Sheet Ā· Consolidated

Balance Sheet Ā· Consolidated ā€” all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assetsā‚¹239.42ā‚¹235.25ā‚¹235.77ā‚¹200.73
Current Assetsā‚¹150.57ā‚¹156.08ā‚¹159.12ā‚¹156.02
Total Assetsā‚¹389.99ā‚¹391.33ā‚¹394.89ā‚¹356.75
Current Liabilitiesā‚¹142.07ā‚¹145.37ā‚¹133.56ā‚¹135.44
Net Current Assetā‚¹8.51ā‚¹10.71ā‚¹25.55ā‚¹20.58
Non-Current Liabilitiesā‚¹35.88ā‚¹52.32ā‚¹73.11ā‚¹56.38
Equity Capitalā‚¹212.05ā‚¹193.64ā‚¹188.22ā‚¹164.93
Total Equity & Liabilitiesā‚¹389.99ā‚¹391.33ā‚¹394.89ā‚¹356.75

Income Statement Ā· Standalone

Income Statement Ā· Standalone ā€” all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenueā‚¹333.37ā‚¹300.00ā‚¹315.24ā‚¹345.63
Other Incomeā‚¹3.95ā‚¹3.84ā‚¹2.88ā‚¹1.54
Total Revenueā‚¹337.32ā‚¹303.84ā‚¹318.12ā‚¹347.16
Total Expensesā‚¹307.28ā‚¹284.73ā‚¹302.10ā‚¹326.88
Profit Before Taxā‚¹30.04ā‚¹19.11ā‚¹18.37ā‚¹32.98
Taxā‚¹8.67ā‚¹6.05ā‚¹5.15ā‚¹7.60
Profit After Taxā‚¹21.37ā‚¹13.07ā‚¹13.22ā‚¹25.38
EPS - Basicā‚¹70.69ā‚¹43.22ā‚¹43.72ā‚¹83.95
EPS - Dilutedā‚¹70.69ā‚¹43.22ā‚¹43.72ā‚¹83.95

Cash Flow Ā· Standalone

Cash Flow Ā· Standalone ā€” all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before taxā‚¹30.04ā‚¹19.11ā‚¹16.02ā‚¹20.28
Income before WC changesā‚¹48.89ā‚¹34.51ā‚¹27.53ā‚¹30.80
Change in Assets-ā‚¹9.82-ā‚¹6.97-ā‚¹7.49-ā‚¹34.55
Change in Liabilities-ā‚¹2.54-ā‚¹9.79-ā‚¹11.97-ā‚¹3.34
Change in WC-ā‚¹12.36-ā‚¹16.76-ā‚¹19.45-ā‚¹37.90
Cash flow from Operationsā‚¹28.03ā‚¹14.75ā‚¹4.58-ā‚¹14.66
Cash flow from Investing-ā‚¹13.77-ā‚¹13.75-ā‚¹27.96-ā‚¹7.49
Cash flow from Financing-ā‚¹14.20-ā‚¹0.82ā‚¹22.59ā‚¹14.63
Total Cash Flowā‚¹0.07ā‚¹0.18-ā‚¹0.80-ā‚¹7.52
Cash (Start of the year)ā‚¹0.33ā‚¹0.15ā‚¹0.95ā‚¹8.46
Cash (End of the year)ā‚¹0.40ā‚¹0.33ā‚¹0.15ā‚¹0.95

Balance Sheet Ā· Standalone

Balance Sheet Ā· Standalone ā€” all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assetsā‚¹180.52ā‚¹172.88ā‚¹169.80ā‚¹149.68
Current Assetsā‚¹177.79ā‚¹175.35ā‚¹167.59ā‚¹162.32
Total Assetsā‚¹358.31ā‚¹348.24ā‚¹337.39ā‚¹312.00
Current Liabilitiesā‚¹124.30ā‚¹123.56ā‚¹110.57ā‚¹118.96
Net Current Assetā‚¹53.49ā‚¹51.79ā‚¹57.03ā‚¹43.35
Non-Current Liabilitiesā‚¹36.84ā‚¹48.45ā‚¹62.80ā‚¹41.83
Equity Capitalā‚¹197.18ā‚¹176.23ā‚¹164.03ā‚¹151.21
Total Equity & Liabilitiesā‚¹358.31ā‚¹348.24ā‚¹337.39ā‚¹312.00
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
1451.3
8
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 8
Buy orders: 0%
Sell orders: 100%
Compare against other stocks
SMS Lifesciences Share Price
SMS Lifesciences
Pharmaceuticals
Add Stock
Add Another

SMS Lifesciences Share Price FAQs

SMS Lifesciences share price data is sourced from NSE/BSE and may be delayed. It is displayed for informational purposes only and does not constitute investment advice or a recommendation to buy or sell.

Trusted by 2 Crore+ Indians for their wealth-building needs. SEBI Registered Broker. SEBI Reg No. INZ000315837